Samsung Biologics says Plant 4 to be partially operational by end of year
Construction of Plant 4 – dubbed Super Plant – will be complete in 2023
Samsung Biologics has said its new “Super Plant” will be partially operational by the end of the year and fully operational by mid-2023, at which time the company is expected to hold the world’s largest biomanufacturing capacity.
Plant 4 is located in the Songdo district of Incheon, South Korea and will boast 256,000 liters total manufacturing capacity once completed, bringing the CDMO’s overall capacity to 620,000 liters. The 238,000-square-meter floorplan makes it the world's largest biopharmaceutical manufacturing facility of its kind.
The company already has a slate of deals lined up for the plant, having secured CMO contracts with three companies for five different products.
Speaking to CPHI Online, CEO John Rim said the new facility would help to meet increasing demand for biologics.
He said: "By utilizing Plant 4, the company aims to meet the increasing demand of manufacturing for large-scale biologics for a wide array of diseases, tailoring the services to the clients’ specific needs.
Having advanced smart plant technologies and flexible scale of capabilities will allow us to provide stable supply for our clients and ultimately contribute to saving the lives of patients".
Rim also addressed Plant 4 progress at last week's 11th Annual General Meeting of Shareholders, where he announced a three-pronged approach to corporate growth.
In an address to shareholders, he said “We are now venturing into the three core pillars of our multidimensional growth plan, encompassing expanded manufacturing capacity, continued advancements in business portfolio, and greater global footprint”.
The company is expected to begin construction on its fifth plant (Plant 5) this year, described by Rim as a “multi modal plant” where “we will offer services beyond the traditional mammalian monoclonal antibodies production”. The plant will also be based in Incheon and is expected to include mRNA vaccine drug substance production capabilities.
Last year the company secured a contract to perform fill-finish manufacturing of Moderna’s COVID-19 vaccine, but Samsung says the mRNA drug substance expansion is unrelated to this deal.
Additionally, the company plans to purchase land for a second Bio Campus with an expected land mass 30% greater than its current campus (Bio Campus I) in Songdo, for the construction of future large scale plants and an Open Innovation Center.
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance